Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density

References

• Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice From the American Gastroenterological Association. Gastroenterology 152(4), 706–715 (2017).
   PubMed Web of Science ®Google Scholar
• Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut. Liver 11(1), 27–37 (2017).
   PubMed Web of Science ®Google Scholar
• Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 32(1), 67–79 (2012).
   PubMed Web of Science ®Google Scholar
• Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur. J. Clin. Pharmacol. 64(10), 935–951 (2008).
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Falk GW, Iyer PG, Gerson LB. American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am. J. Gastroenterol. 111(1), 30–50; quiz 51 (2016).
   PubMed Web of Science ®Google Scholar
• Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am. J. Gastroenterol. 112(7), 988–1013 (2017).
   PubMed Web of Science ®Google Scholar
• Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 108(3), 308–328; quiz 329 (2013).
   PubMed Web of Science ®Google Scholar
• Targownik LE, Leslie WD, Davison KS et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am. J. Gastroenterol. 107(9), 1361–1369 (2012).
   PubMed Web of Science ®Google Scholar
• Romdhane H, Ayadi S, Elleuch N, Abdelghani K. Effect of long-term proton pump inhibitors on bone mineral density. Tunis. Med. 96(3), 193–197 (2018).
   PubMedGoogle Scholar
• Recart DA, Ferraris A, Petriglieri CI, Alonso Serena M, Bonella MB, Posadas-Martinez ML. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients. Intern. Emerg. Med. 16(3), 711–717 (2021).
   PubMed Web of Science ®Google Scholar
• Cabras P, Anedda M, Caddeo L, Francesco M, Antonella M. Hypomagnesemia and hypocalcemia caused by proton-pump inhibitors long-term therapy. Am. J. Ther. 27(6), e676–680 (2020).
   PubMed Web of Science ®Google Scholar
• Luk CP, Parsons R, Lee YP, Hughes JD. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann. Pharmacother. 47(6), 773–780 (2013).
   PubMed Web of Science ®Google Scholar
• Wakeman M. A Literature Review of the Potential Impact of Medication on Vitamin D Status. Risk. Manag. Healthc. Policy. 14, 3357–3381 (2021).
   PubMed Web of Science ®Google Scholar
• Janett S, Camozzi P, Peeters GGAM et al. Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors. Gastroenterol. Res. Pract. 2015, 951768 (2015).
   PubMed Web of Science ®Google Scholar
• Koulouridis I, Alfayez M, Tighiouart H et al. Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am. J. Kidney Dis. 62(4), 730–737 (2013).
   PubMed Web of Science ®Google Scholar
• Losurdo G, Caccavo NLB, Indellicati G et al. Effect of long-term proton pump inhibitor use on blood vitamins and minerals: a primary care setting study. J. Clin. Med. 12(8), 2910 (2023).
   PubMed Web of Science ®Google Scholar
• Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 139(4), 1115–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Hinson AM, Wilkerson BM, Rothman-Fitts I, Riggs AT, Stack BC, Bodenner DL. Hyperparathyroidism associated with long-term proton pump inhibitors independent of concurrent bisphosphonate therapy in elderly adults. J. Am. Geriatr. Soc. 63(10), 2070–2073 (2015).
   PubMed Web of Science ®Google Scholar
• Fatuzzo P, Portale G, Scollo V, Zanoli L, Granata A. Proton pump inhibitors and symptomatic hypomagnesemic hypoparathyroidism. J. Nephrol. 30(2), 297–301 (2017).
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Khan A, Potts JT et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26(10), 2317–2337 (2011).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Acute-onset hypomagnesemia-induced hypocalcemia caused by the refractoriness of bones and renal tubules to parathyroid hormone. J. Bone. Miner. Metab. 29(6), 752–755 (2011).
   PubMed Web of Science ®Google Scholar
• Famularo G, Gasbarrone L, Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert. Opin. Drug. Saf. 12(5), 709–716 (2013).
   PubMed Web of Science ®Google Scholar
• Amling M, Barvencik F. Calcium and vitamin D in osteology. Z. Rheumatol. 74(5), quiz 433–4 (2015).
   Web of Science ®Google Scholar
• Attwood SE, Ell C, Galmiche JP et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment. Pharmacol. Ther. 41(11), 1162–1174 (2015).
   PubMed Web of Science ®Google Scholar
• Van Orten-Luiten ACB, Janse A, Dhonukshe-Rutten RAM, Witkamp RF. The association between drugs frequently used by the elderly and vitamin D blood levels: a review of observational and experimental studies. Drugs Aging 31(2), 111–123 (2014).
   PubMed Web of Science ®Google Scholar
• Sohl E, van Schoor NM, de Jongh RT, de Vries OJ, Lips P. The impact of medication on vitamin D status in older individuals. Eur. J. Endocrinol. 166(3), 477–485 (2012).
   PubMed Web of Science ®Google Scholar
• Wright MJ, Sullivan RR, Gaffney-Stomberg E et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J. Bone Miner. Res. 25(10), 2205–2211 (2010).
   PubMed Web of Science ®Google Scholar
• Hansen KE, Jones AN, Lindstrom MJ et al. Do Proton Pump Inhibitors Decrease Calcium Absorption? J. Bone Miner. Res. 25(12), 2786–2795 (2010).
   PubMed Web of Science ®Google Scholar
• Sharara AI, El-Halabi MM, Ghaith OA et al. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism 62(4), 518–526 (2013).
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 153(1), 35–48 (2017).
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin CL, Kao CH. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos. Int. 27(6), 2117–2126 (2016).
   PubMed Web of Science ®Google Scholar
• Van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters GMEEG. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone 81, 675–682 (2015).
   PubMed Web of Science ®Google Scholar
• Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue. Int. 83(4), 251–259 (2008).
   PubMed Web of Science ®Google Scholar
• De Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos. Int. 20(12), 1989–1998 (2009).
   PubMed Web of Science ®Google Scholar
• Roux C, Briot K, Gossec L et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif. Tissue. Int. 84(1), 13–19 (2009).
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947–2953 (2006).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Sugimoto T, Yamauchi M, Matsumori Y, Tsutsumi M, Chihara K. Multiple vertebral fractures are associated with refractory reflux esophagitis in postmenopausal women. J. Bone. Miner. Metab. 23(1), 36–40 (2005).
   PubMed Web of Science ®Google Scholar
• Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28(8), 951–959 (2008).
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch. Intern. Med. 171(11), 998–1004 (2011).
   PubMedGoogle Scholar
• Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch. Intern. Med. 170(9), 765–771 (2010).
   PubMedGoogle Scholar
• Corley DA, Kubo A, Zhao W, Quesenberry C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists are Associated with Hip Fractures among At-Risk Patients. Gastroenterology 139(1), 93–101 (2010).
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif. Tissue. Int. 79(2), 76–83 (2006).
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3), 896–904 (2010).
   PubMed Web of Science ®Google Scholar
• Pouwels S, Lalmohamed A, Souverein P et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos. Int. 22(3), 903–910 (2011).
   PubMed Web of Science ®Google Scholar
• Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 179(4), 319–326 (2008).
   PubMed Web of Science ®Google Scholar
• Chiu HF, Huang YW, Chang CC, Yang CY. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol. Drug. Saf. 19(11), 1131–1136 (2010).
   PubMed Web of Science ®Google Scholar
• Maggio M, Lauretani F, Ceda GP et al. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals. Bone 57(2), 437–442 (2013).
   PubMed Web of Science ®Google Scholar
• Lespessailles E, Toumi H. Proton pump inhibitors and bone health: an update narrative review. Int. J. Mol. Sci. 23(18), 10733 (2022).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Nevitt MC et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 263(5), 665–668 (1990).
   PubMed Web of Science ®Google Scholar
• Orwoll E, Blank JB, Barrett-Connor E et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study -a large observational study of the determinants of fracture in older men. Contemp. Clin. Trials. 26(5), 569–585 (2005).
   PubMed Web of Science ®Google Scholar
• Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann. Epidemiol. 13(Suppl. 9), S107–S121 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon DH, Diem SJ, Ruppert K et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J. Bone Miner. Res. 30(2), 232–239 (2015).
   PubMed Web of Science ®Google Scholar
• Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos. Int. 27(1), 339–347 (2016).
   PubMed Web of Science ®Google Scholar
• Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J. Bone. Metab. 25(3), 141–151 (2018).
   PubMedGoogle Scholar
• Aleraij S, Alhowti S, Ferwana M, Abdulmajeed I. Effect of proton pump inhibitors on bone mineral density: a systematic review and meta-analysis of observational studies. Bone. Rep. 13, 100732 (2020).
   PubMedGoogle Scholar
• Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J. Bone Miner. Res. 26(11), 2762–2769 (2011).
   PubMed Web of Science ®Google Scholar
• Lee J, Youn K, Choi NK et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J. Gastroenterol. 48(9), 1016–1022 (2013).
   PubMed Web of Science ®Google Scholar
• Lewis JR, Barre D, Zhu K et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J. Bone Miner. Res. 29(11), 2489–2497 (2014).
   PubMed Web of Science ®Google Scholar
• Lenihan CR, Sukumaran Nair S, Vangala C, Ramanathan V, Montez-Rath ME, Winkelmayer WC. Proton pump inhibitor use and risk of hip fracture in kidney transplant recipients. Am. J. Kidney Dis. 69(5), 595–601 (2017).
   PubMed Web of Science ®Google Scholar
• Torvinen-Kiiskinen S, Tolppanen AM, Koponen M et al. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease-a nested case-control study. Aliment. Pharmacol. Ther. 47(8), 1135–1142 (2018).
   PubMed Web of Science ®Google Scholar
• Wang L, Li M, Cao Y et al. Proton pump inhibitors and the risk for fracture at specific sites: data mining of the FDA adverse event reporting system. Sci. Rep. 7(1), 5527 (2017).
   PubMedGoogle Scholar
• Vangala C, Niu J, Lenihan CR, Mitch WE, Navaneethan SD, Winkelmayer WC. Proton Pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 13(10), 1534–1541 (2018).
   PubMed Web of Science ®Google Scholar
• Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann. Epidemiol. 24(4), 286–290 (2014).
   PubMed Web of Science ®Google Scholar
• Cea Soriano L, Ruigómez A, Johansson S, García Rodríguez LA. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting. Pharmacotherapy 34(6), 570–581 (2014).
   PubMed Web of Science ®Google Scholar
• Van der Hoorn MMC, Tett SE, de Vries OJ, Dobson AJ, Peeters GMEEG. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone 81, 675–682 (2015).
   PubMed Web of Science ®Google Scholar
• Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD. CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos. Int. 24(4), 1161–1168 (2013).
   PubMed Web of Science ®Google Scholar
• Moberg LM, Nilsson PM, Samsioe G, Borgfeldt C. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study. Maturitas. 78(4), 310–315 (2014).
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Haynes K, Denburg MR et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. Osteoporos. Int. 26(10), 2501–2507 (2015).
   PubMed Web of Science ®Google Scholar
• Ding J, Heller DA, Ahern FM, Brown TV. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. Calcif. Tissue. Int. 94(6), 597–607 (2014).
   PubMed Web of Science ®Google Scholar
• Lin SM, Yang SH, Liang CC, Huang HK. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study. Osteoporos. Int. 29(1), 153–162 (2018).
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin CL, Kao CH. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis. Osteoporos. Int. 27(6), 2117–2126 (2016).
   PubMed Web of Science ®Google Scholar
• Harding BN, Weiss NS, Walker RL, Larson EB, Dublin S. Proton pump inhibitor use and the risk of fractures among an older adult cohort. Pharmacoepidemiol. Drug Saf. 27(6), 596–603 (2018).
   Web of Science ®Google Scholar
• Lai SW, Lin CH, Lin CL, Liao KF. Proton pump inhibitors therapy and the risk of hip fracture in older people in Taiwan. Eur. Geriatr. Med. 9(2), 169–174 (2018).
   PubMed Web of Science ®Google Scholar
• Reyes C, Formiga F, Coderch M et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone 52(2), 557–561 (2013).
   PubMed Web of Science ®Google Scholar
• Poly TN, Islam MM, Yang HC, Wu CC, Li YCJ. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos. Int. 30(1), 103–114 (2019).
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Watarai K, Oda T, Kim YT, Oda H. Proton pump inhibitors and fracture: they impair bone quality and increase fall risk? Osteoporos. Int. 27(4), 1675–1676 (2016).
   PubMed Web of Science ®Google Scholar
• Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures. Curr. Treat. Options. Gastro. 12(4), 414–423 (2014).
   PubMedGoogle Scholar
• Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am. J. Gastroenterol. 106(7), 1209–1218; quiz 1219 (2011).
   PubMed Web of Science ®Google Scholar